Iray Group688301.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Iray Group (688301.SH) trades at a P/E of 31.70x, P/B of 2.97x, P/S of 6.85x, and a dividend yield of 0.92%.
Longitudinal percentile comparison: P/E sits at the 11th percentile over the trailing 10Y window (vs. 22nd percentile over 3Y); P/B sits at the 2nd percentile over the trailing 10Y window (vs. 3rd percentile over 3Y); P/S sits at the 2nd percentile over the trailing 10Y window (vs. 5th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 43rd percentile within its industry and the 44th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.34%, ranking at the 92nd percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 9.7 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 1.34% total shareholder yield, 0.92% is paid out as dividends and roughly 0.42% is implied to come from buybacks — both channels are meaningfully in play. Iray Group operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 688301 · SSE: 688301 · 688301
Want the full picture on whether Iray Group (688301.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 31.70 | ||||||
| P/B (MRQ) | 2.97 | ||||||
| P/S (TTM) | 6.85 | ||||||
| Dividend Yield | 0.92% | ||||||
| Buyback + Div Yield | 1.34% |